<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785833</url>
  </required_header>
  <id_info>
    <org_study_id>PA-CART-3-17-001</org_study_id>
    <nct_id>NCT04785833</nct_id>
  </id_info>
  <brief_title>CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia</brief_title>
  <official_title>A Prospective, Open, Single-arm Clinical Study on the Efficacy and Safety of CD7 CAR-T in the Treatment of CD7-positive Refractory Relapsed Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute leukemia derived from T lymphocytes have the characteristics of high&#xD;
      expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to&#xD;
      genetically modify the patient's T lymphocytes to target and eliminate tumor cells in a major&#xD;
      histocompatibility complex-independent manner. CAR-T cells are costimulatory molecules that&#xD;
      include single-chain antibodies (scFv) that recognize tumor-specific antigens, hinge regions,&#xD;
      transmembrane regions, intracellular signaling regions (immunoreceptor tyrosine activation&#xD;
      motif ITAM), and intracellular signaling regions. The chimeric antigen receptor of CD28 or&#xD;
      CD137(4-1BB) conduction domain is expressed in a lentiviral vector, and the vector is&#xD;
      transfected into autologous T cells, so that the modified CAR-T cells have targeting and&#xD;
      specificity Recognizes and kills cancer cells expressing tumor antigens, and can proliferate&#xD;
      and activate in vivo, but has no effect on cells that do not express the antigen&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 4, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety results</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The maximum concentration (Cmax）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Absolute value of CD7 Positive Cells in peripheral blood at each time point</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>T-ALL</condition>
  <arm_group>
    <arm_group_label>T cell injection targeting CD7 chimeric antigen receptor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T cell injection targeting CD7 chimeric antigen receptor</intervention_name>
    <description>Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation</description>
    <arm_group_label>T cell injection targeting CD7 chimeric antigen receptor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 12-65&#xD;
&#xD;
          -  Sign informed consent&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  CD7 positive refractory and relapsed acute leukemia&#xD;
&#xD;
          -  Karnofsky score≥60&#xD;
&#xD;
          -  ECOG score ≤ 2&#xD;
&#xD;
          -  Have not received other immunotherapy within 3 months&#xD;
&#xD;
          -  The CD7 expression rate on the surface of leukemia cells detected by flow cytometry is&#xD;
             greater than 30%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Active viral hepatitis B or C&#xD;
&#xD;
          -  HIV test positive&#xD;
&#xD;
          -  Congenital immunodeficiency patients&#xD;
&#xD;
          -  Pregnant and breastfeeding patients&#xD;
&#xD;
          -  Patients with central nervous system tumors or central nervous system leukemia&#xD;
&#xD;
          -  The patient and/or family members do not agree to the treatment plan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaowen tang</last_name>
    <phone>13913538266</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>huimin meng</last_name>
    <phone>18896802149</phone>
    <email>huimin.meng@persongen.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliared Hospital Of SOOCHOW University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaowen tang</last_name>
      <phone>13913538266</phone>
      <email>xwtang1020@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

